Investigation and analysis of infection and antibiotic resistance of Helicobacter pylori in armed policemen in Shaanxi province / 解放军医学杂志

ABSTRACT

Objective To investigate and analyze the situation of Helicobacter pylori (Hp) infection and antibiotic resistance in armed police officers and soldiers (APOSs) in Shaanxi province, and provide a theoretical basis for the rational selection of drugs for the eradication of Hp in the armed police forces in this region. Methods Two hundred and three APOS patients from the Shaanxi Armed Police Corps Hospital who underwent gastroscopy for gastrointestinal symptoms from June 2016 to December 2017 were enrolled in this study. Biopsy samples were extracted by gastroscope and Hp was isolated, identified and cultured. Four types of antibiotics were used to analyze the sensitivity of resistance to drugs amoxicillin, clarithromycin, levofloxacin and metronidazole. Results A total of 119 Hp strains were isolated from 203 endoscopic biopsies. The positivity rate was 58.6%. The positivity rate of Hp isolation and culture in patients with peptic ulcer was 58.1% (36/62), which was significantly higher than that in patients with chronic gastritis (35.2%, 32/91, χ2=7.832, P=0.005); There was no statistical difference compared with other pathological types of diseases (P>0.05). The resistance rates of Hp to amoxicillin, clarithromycin, levofloxacin, and metronidazole were 1.7% (2/119), 10.1% (12/119), 14.3% (17/119) and 28.6% (34/119), respectively. There were 12 of 119 strains were detected to be resistant to two drugs, of them 7 were resistant to clarithromycin and metronidazole, and 5 were resistant to levofloxacin and clarithromycin. We did not find the strains which are antibiotic resistant to three or more drugs. There was no significant difference in Hp resistance between different pathological disease types (P>0.05). Conclusions The role of Hp in the development of peptic ulcers among local armed police officers is very important. The current first-line therapy should be selected for eradication treatment of APOS patients in the region.